Ament, Seth APearl, Jocelynn RCantle, Jeffrey PBragg, Robert MSkene, Peter JCoffey, Sydney RBergey, Dani EWheeler, VanessaMacDonald, MarcyBaliga, Nitin SRosinski, JimHood, Leroy ECarroll, Jeffrey BPrice, Nathan D2018-04-192018Ament, S. A., J. R. Pearl, J. P. Cantle, R. M. Bragg, P. J. Skene, S. R. Coffey, D. E. Bergey, et al. 2018. “Transcriptional regulatory networks underlying gene expression changes in Huntington's disease.” Molecular Systems Biology 14 (3): e7435. doi:10.15252/msb.20167435. http://dx.doi.org/10.15252/msb.20167435.http://nrs.harvard.edu/urn-3:HUL.InstRepos:35981943Abstract Transcriptional changes occur presymptomatically and throughout Huntington's disease (HD), motivating the study of transcriptional regulatory networks (TRNs) in HD. We reconstructed a genome‐scale model for the target genes of 718 transcription factors (TFs) in the mouse striatum by integrating a model of genomic binding sites with transcriptome profiling of striatal tissue from HD mouse models. We identified 48 differentially expressed TF‐target gene modules associated with age‐ and CAG repeat length‐dependent gene expression changes in Htt CAG knock‐in mouse striatum and replicated many of these associations in independent transcriptomic and proteomic datasets. Thirteen of 48 of these predicted TF‐target gene modules were also differentially expressed in striatal tissue from human disease. We experimentally validated a specific model prediction that SMAD3 regulates HD‐related gene expression changes using chromatin immunoprecipitation and deep sequencing (ChIP‐seq) of mouse striatum. We found CAG repeat length‐dependent changes in the genomic occupancy of SMAD3 and confirmed our model's prediction that many SMAD3 target genes are downregulated early in HD.en-USArticleHuntington's diseasetranscription factortranscriptional regulatory networksGenome-Scale & Integrative BiologyMolecular Biology of DiseaseNetwork BiologyJournal Article2018-04-1910.15252/msb.20167435